Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6

GLP-1 RA (glucagon-like peptide-1 receptor agonists), including semaglutide, may reduce stroke risk in people with type 2 diabetes. This post hoc analysis examined the subcutaneous and oral semaglutide effects, versus placebo, on stroke and its subtypes in people with type 2 diabetes at high cardiov...

Descripción completa

Detalles Bibliográficos
Autores principales: Strain, W. David, Frenkel, Ofir, James, Martin A., Leiter, Lawrence A., Rasmussen, Søren, Rothwell, Peter M., Sejersten Ripa, Maria, Truelsen, Thomas C., Husain, Mansoor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389936/
https://www.ncbi.nlm.nih.gov/pubmed/35582947
http://dx.doi.org/10.1161/STROKEAHA.121.037775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389936/
https://www.ncbi.nlm.nih.gov/pubmed/35582947
http://dx.doi.org/10.1161/STROKEAHA.121.037775

Ejemplares similares